KSE - Delayed Quote KRW

Korea United Pharm Inc. (033270.KS)

Compare
18,830.00 +250.00 (+1.35%)
At close: 3:30:30 PM GMT+9
Loading Chart for 033270.KS
DELL
  • Previous Close 18,580.00
  • Open 18,600.00
  • Bid 18,830.00 x --
  • Ask 18,890.00 x --
  • Day's Range 18,570.00 - 19,050.00
  • 52 Week Range 17,250.00 - 27,200.00
  • Volume 21,502
  • Avg. Volume 27,217
  • Market Cap (intraday) 277.014B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Mar 17, 2025 - Mar 21, 2025
  • Forward Dividend & Yield 420.00 (2.27%)
  • Ex-Dividend Date Dec 27, 2023
  • 1y Target Est --

Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.

www.kup.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 033270.KS

View More

Performance Overview: 033270.KS

Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

033270.KS
3.40%
KOSPI Composite Index
3.72%

1-Year Return

033270.KS
30.00%
KOSPI Composite Index
3.47%

3-Year Return

033270.KS
57.30%
KOSPI Composite Index
14.79%

5-Year Return

033270.KS
13.06%
KOSPI Composite Index
15.48%

Compare To: 033270.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 033270.KS

View More

Valuation Measures

As of 1/3/2025
  • Market Cap

    273.34B

  • Enterprise Value

    182.35B

  • Trailing P/E

    13.25

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.95

  • Price/Book (mrq)

    0.70

  • Enterprise Value/Revenue

    0.64

  • Enterprise Value/EBITDA

    4.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.40%

  • Return on Assets (ttm)

    6.78%

  • Return on Equity (ttm)

    12.21%

  • Revenue (ttm)

    161.44B

  • Net Income Avi to Common (ttm)

    20.02B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.2B

  • Total Debt/Equity (mrq)

    13.85%

  • Levered Free Cash Flow (ttm)

    11.34B

Research Analysis: 033270.KS

View More

People Also Watch